Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS

ZeNewCardio: Discovering Heart Regeneration Therapies Through Zebrafish

Project description

Self-healing of the heart

Cardiac infarction is caused by reduced oxygen flow to the heart and may lead to tissue necrosis and heart failure. Cardiac tissue exhibits little regenerative capacity, while available treatment options are limited and largely ineffective. The EU-funded ZeNewCardio project is working on identifying the key players that block endogenous myocardial recovery after infarction. Researchers will use zebrafish as a model organism to identify genes involved in heart regeneration and test various treatments. Given the restricted availability of heart donors for transplantation and the millions of heart disease sufferers, ZeNewCardio is paving the way for an alternative regenerative intervention.

Objective

Ischemic heart disease is a leading cause of death worldwide. However, heart transplantation is risky, plus the number of donors does not cover the demand of patients, and alternative treatments are inefficient. Given that adult mammalian hearts display insufficient regeneration capability to allow complete myocardial recovery, a promising treatment after infarction could be the identification of molecules unblocking cardiac self-healing/regeneration. In that sense, zebrafish displays life-long ability to regenerate its heart after damage. Interestingly, the same genetic programs promoting cardiomyocyte dedifferentiation and proliferation after injury in zebrafish are present, albeit dormant, in the adult mammalian heart. This makes zebrafish a powerful model to unravel key molecular pathways that might induce heart regeneration in humans, if activated. Here, we propose the development of ZeNewCardio: a high-throughput preclinical platform using the zebrafish model to find suitable treatments for heart regeneration after ischemia. The project aims are: 1) to implement cardiac injury models in zebrafish; 2) to use these models to identify genes involved in heart regeneration, with a focus on genes enabling cardiomyocyte dedifferentiation/proliferation; 3) to use the gathered knowledge to discover novel cardiac pro-regeneration drug therapies applicable to humans. Our genetic and analysis tools will speed-up the process of target validation of novel gene regulators of regeneration, based on the stimulation of endogenous regenerative responses, and the discovery of new drug therapies to treat or protect ischemic hearts.

Coordinator

ZECLINICS SL
Net EU contribution
€ 160 932,48
Address
CTRA LAUREA MIRO, NUM 408, POLIGONO INDUSTRIAL EL PLA
08980 SANT FELIU DE LLOBREGAT
Spain

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Este Cataluña Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 160 932,48